Department of Thoracic Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Thoracic Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
Interact Cardiovasc Thorac Surg. 2022 Jul 9;35(2). doi: 10.1093/icvts/ivac062.
This study aimed to evaluate the prognostic impact of the combination of epidermal growth factor receptor (EGFR) mutation and the presence of high-grade patterns (solid or micropapillary component) in resected stage I lung adenocarcinoma.
Patients who underwent curative resection for pathological stage I lung adenocarcinoma and EGFR mutation analysis were included in this study. The impact of the combination of EGFR mutation and the presence of >5% high-grade patterns on recurrence-free survival (RFS) was retrospectively analysed using Cox proportional hazards model and propensity score-matched analysis.
Among the included 721 patients, EGFR mutations were positive in 380 (52.7%). In the EGFR-mutated group, cases with high-grade patterns showed poorer RFS than those without (5-year RFS, 77.7% vs 92.5%, P < 0.001), whereas there were no significant prognostic differences in the EGFR wild-type group (5-year RFS, 89.8% vs 88.2%, P = 0.807). Multivariable analyses revealed that the combination of EGFR mutations and the presence of high-grade patterns was associated with poor RFS (hazard ratio = 1.655, P = 0.035). Furthermore, EGFR mutation was associated with poor RFS in the group with high-grade patterns (hazard ratio = 2.108, P = 0.008). After propensity score matching, EGFR-mutated cases with high-grade patterns showed poorer RFS (P = 0.028).
The combination of EGFR mutation and the presence of high-grade patterns was associated with recurrence in resected stage I lung adenocarcinoma. Histological subtypes, including minor components, should be considered when evaluating the risk of recurrence in patients with EGFR-mutated lung adenocarcinoma.
本研究旨在评估表皮生长因子受体(EGFR)突变与切除的 I 期肺腺癌中高级别形态(实性或微乳头状成分)存在的联合对预后的影响。
本研究纳入了接受根治性切除术治疗病理 I 期肺腺癌且 EGFR 突变分析的患者。使用 Cox 比例风险模型和倾向评分匹配分析回顾性分析 EGFR 突变与 >5%高级别形态并存对无复发生存(RFS)的影响。
在纳入的 721 例患者中,EGFR 突变阳性 380 例(52.7%)。在 EGFR 突变组中,存在高级别形态的病例 RFS 较差(5 年 RFS,77.7%比 92.5%,P <0.001),而 EGFR 野生型组的预后差异无统计学意义(5 年 RFS,89.8%比 88.2%,P=0.807)。多变量分析显示,EGFR 突变与高级别形态的存在与不良 RFS 相关(风险比=1.655,P=0.035)。此外,在高级别形态组中,EGFR 突变与 RFS 不良相关(风险比=2.108,P=0.008)。经过倾向评分匹配后,存在高级别形态的 EGFR 突变病例 RFS 较差(P=0.028)。
EGFR 突变与高级别形态的存在与切除的 I 期肺腺癌的复发相关。在评估 EGFR 突变型肺腺癌患者的复发风险时,应考虑包括次要成分在内的组织学亚型。